Prostate Cancer Coverage from Every Angle

Kim N. Chi, MD, on Adding Apalutamide to Androgen-Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer

Posted: Monday, June 17, 2019

Kim N. Chi, MD, of BC Cancer, discusses treating metastatic castration-sensitive prostate cancer by adding apalutamide to androgen-deprivation therapy now that phase III findings from the TITAN study showed improved radiographic progression-free and overall survival.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.